Quantcast

Latest lung cancer Stories

2014-05-20 12:33:19

Oncoprex Combined with Tarceva for Patients With and Without EGFR Mutations AUSTIN, Texas, May 20, 2014 /PRNewswire/ -- Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex® in combination with erlotinib (Tarceva®) for late-stage lung cancer patients. Oncoprex is a targeted biologic incorporating the pan-kinase inhibitor TUSC2, which inhibits oncogenic kinases via multiple pathways. The trial is...

2014-05-19 23:02:53

Transparency Market Research Report Added "Adjuvants Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2012 - 2018" to its database. Browse Full Report: http://www.transparencymarketresearch.com/adjuvants-market.html. Albany, New York, USA (PRWEB) May 19, 2014 Adjuvant oncology treatment comprises of a class of cancer therapeutics which is followed after primary cancer treatment, to minimize the risk of reoccurrence of cancer. The major forms of...

2014-05-15 23:06:12

Local Stem Cell Clinic Celebrates Anniversary with Hundreds of Patients Treated Tampa, Florida (PRWEB) May 15, 2014 On Tuesday, May 20, Lung Institute is celebrating the first anniversary of its Tampa location. As a leader in regenerative medicine, Lung Institute has provided over 250 treatments to lung disease patients who previously had no hope for better breathing and regaining quality of life. Lung Institute treats lung diseases including pulmonary fibrosis and chronic obstructive...

2014-05-15 23:00:47

Created by Society for Immunotherapy of Cancer, this video was created to raise awareness about the excitement and the hope cancer immunotherapy clinical trials can offer patients with NSCLC today. Milwaukee, WI (PRWEB) May 15, 2014 A recently released video on cancer immunotherapy is offering new hope to patients with non-small cell lung cancer (NSCLC), the type of cancer which makes up 85% to 90% of all lung cancer cases in the US and claims more lives each year than colon, breast, and...

2014-05-14 20:23:28

-- Results from two Phase III studies (LUX-Lung 3 and LUX-Lung 6) add to the body of evidence supporting the importance of first-line treatment with afatinib in patients whose tumors express the EGFR exon 19 deletion mutation RIDGEFIELD, Conn., May 14, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced new overall survival data of two Phase III clinical trials (LUX-Lung 3 and LUX-Lung 6). Patients with advanced non-small cell lung cancer (NSCLC) whose tumors have the most common...

2014-05-14 16:28:57

-- Difficult-to-treat squamous NSCLC patients saw clinical benefit with necitumumab plus chemotherapy regimen -- INDIANAPOLIS, May 14, 2014 /PRNewswire/ -- Lung cancer patients with metastatic squamous cell carcinoma have seen few treatment advancements over the last two decades, leaving these patients with a poor prognosis. This is in contrast to the progress seen in nonsquamous non-small cell lung cancer (NSCLC).[1] Results from the largest ever Phase III trial in first-line...

2014-05-14 16:28:52

This early phase study also evaluated an abemaciclib combination in hormone receptor positive metastatic breast cancer patients INDIANAPOLIS, May 14, 2014 /PRNewswire/ -- Abemaciclib, an oral drug administered twice daily, currently in development by Eli Lilly and Company (NYSE: LLY), has shown evidence of single-agent activity in patients with advanced non-small cell lung cancer in a Phase I study released ahead of the American Society of Clinical Oncology (ASCO) Annual Meeting to...

2014-05-13 16:28:15

Lung Cancer Became the Leading Cause of Cancer Death Among Women in the 1980's WASHINGTON, May 13, 2014 /PRNewswire-USNewswire/ -- Lung Cancer Alliance praised American Lung Association on its launch of LUNG FORCE, an initiative aimed at raising awareness among women about lung cancer. "We welcome the American Lung Association's help in bringing attention to the fact that lung cancer is the leading cause of cancer death among women - an appropriate and important message during...

2014-05-13 08:31:14

CVS Caremark signs on as national presenting sponsor to raise awareness of the #1 cancer killer of women CHICAGO, May 13, 2014 /PRNewswire/ -- Today, the American Lung Association, in partnership with national presenting sponsor, CVS Caremark, unveiled LUNG FORCE, a new initiative to make lung cancer in women a public health priority, drive policy change and increase research funding. To view the multimedia assets associated with this release, please click:...

2014-05-09 23:04:46

Markets Research Reports.biz added deep and professional market research reports on "Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2014" analysis and overview. (PRWEB) May 09, 2014 Small-Cell Lung Cancer Global Clinical Trials Review, H1, 2014 provides data on the Small-Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Small-Cell Lung Cancer. It includes an overview of the trial numbers...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »
Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related